Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

B. Moriyama, A. Owusu Obeng, J. Barbarino, Scott Robert Penzak, S. A. Henning, S. A. Scott, J. A.G. Agúndez, J. R. Wingard, H. L. McLeod, T. E. Klein, S. J. Cross, K. E. Caudle, T. J. Walsh

Research output: Contribution to journalArticleResearchpeer-review

33 Citations (Scopus)

Abstract

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number1
DOIs
StatePublished - 1 Jul 2017

Fingerprint

Pharmacogenetics
Guidelines
Triazoles
Antifungal Agents
Therapeutic Uses
Drug-Related Side Effects and Adverse Reactions
Therapeutics
Alleles
Genotype
Serum
Voriconazole
Cytochrome P-450 CYP2C19

Cite this

Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, S. R., Henning, S. A., Scott, S. A., ... Walsh, T. J. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clinical Pharmacology and Therapeutics, 102(1), 45-51. https://doi.org/10.1002/cpt.583
Moriyama, B. ; Obeng, A. Owusu ; Barbarino, J. ; Penzak, Scott Robert ; Henning, S. A. ; Scott, S. A. ; Agúndez, J. A.G. ; Wingard, J. R. ; McLeod, H. L. ; Klein, T. E. ; Cross, S. J. ; Caudle, K. E. ; Walsh, T. J. / Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. In: Clinical Pharmacology and Therapeutics. 2017 ; Vol. 102, No. 1. pp. 45-51.
@article{b235a84e47ba4018be812da0eb150e47,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy",
abstract = "Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).",
author = "B. Moriyama and Obeng, {A. Owusu} and J. Barbarino and Penzak, {Scott Robert} and Henning, {S. A.} and Scott, {S. A.} and Ag{\'u}ndez, {J. A.G.} and Wingard, {J. R.} and McLeod, {H. L.} and Klein, {T. E.} and Cross, {S. J.} and Caudle, {K. E.} and Walsh, {T. J.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/cpt.583",
language = "English",
volume = "102",
pages = "45--51",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Wiley-Blackwell",
number = "1",

}

Moriyama, B, Obeng, AO, Barbarino, J, Penzak, SR, Henning, SA, Scott, SA, Agúndez, JAG, Wingard, JR, McLeod, HL, Klein, TE, Cross, SJ, Caudle, KE & Walsh, TJ 2017, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy', Clinical Pharmacology and Therapeutics, vol. 102, no. 1, pp. 45-51. https://doi.org/10.1002/cpt.583

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. / Moriyama, B.; Obeng, A. Owusu; Barbarino, J.; Penzak, Scott Robert; Henning, S. A.; Scott, S. A.; Agúndez, J. A.G.; Wingard, J. R.; McLeod, H. L.; Klein, T. E.; Cross, S. J.; Caudle, K. E.; Walsh, T. J.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. 1, 01.07.2017, p. 45-51.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

AU - Moriyama, B.

AU - Obeng, A. Owusu

AU - Barbarino, J.

AU - Penzak, Scott Robert

AU - Henning, S. A.

AU - Scott, S. A.

AU - Agúndez, J. A.G.

AU - Wingard, J. R.

AU - McLeod, H. L.

AU - Klein, T. E.

AU - Cross, S. J.

AU - Caudle, K. E.

AU - Walsh, T. J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

AB - Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=85018532893&partnerID=8YFLogxK

U2 - 10.1002/cpt.583

DO - 10.1002/cpt.583

M3 - Article

VL - 102

SP - 45

EP - 51

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -